Fabian Muller
Overview
Explore the profile of Fabian Muller including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
159
Citations
5154
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Scholz J, Stabel L, Schwingen N, Knopf J, Flatt A, Bauerle T, et al.
Haematologica
. 2025 Feb;
PMID: 39945024
Not available.
2.
Kittler S, Muller F, Elshazly M, Wandrey G, Klein T, Daub A, et al.
BMC Biotechnol
. 2025 Jan;
25(1):13.
PMID: 39891175
Background: Proteases are essential in various industries due to their unique substrate specificities and robustness in different operational conditions. Bacillus strains consist of a genotype favorable for rapid growth whilst...
3.
Tur C, Eckstein M, Velden J, Rauber S, Bergmann C, Auth J, et al.
Ann Rheum Dis
. 2025 Jan;
84(1):106-114.
PMID: 39874224
Objectives: CD19-targeting chimeric antigen receptor (CAR) T-cell therapy can induce long-term drug-free remission in patients with autoimmune diseases (AIDs). The efficacy of CD19-CAR T-cell therapy is presumably based on deep...
4.
Merz M, Albici A, von Tresckow B, Rathje K, Fenk R, Holderried T, et al.
Hemasphere
. 2025 Jan;
9(1):e70070.
PMID: 39822585
Idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel) have revolutionized the treatment of relapsed/refractory multiple myeloma (RRMM), but direct comparisons are lacking. Leveraging an international multicenter RRMM cohort, we compared the...
5.
Tian X, Esmaeili H, Minich D, Seitz F, Roessner P, Wind S, et al.
Pharmacotherapy
. 2024 Dec;
45(2):94-103.
PMID: 39727284
Introduction: Zongertinib (BI 1810631) is a potent, selective, and epidermal growth factor receptor (EGFR) wild-type sparing human epidermal growth factor receptor 2 (HER2) inhibitor. Based on in vitro data, the...
6.
Merz M, Dima D, Hashmi H, Ahmed N, Stolzel F, Holderried T, et al.
Blood Cancer J
. 2024 Dec;
14(1):214.
PMID: 39632797
Despite the astonishing outcomes after chimeric antigen receptor (CAR) T-cell therapy for relapsed refractory multiple myeloma (RRMM), most patients eventually relapse. There are only limited data available on salvage therapies...
7.
Hagen M, Muller F, Wirsching A, Kharboutli S, Sporl S, Aigner M, et al.
Lancet
. 2024 Nov;
404(10468):2158-2160.
PMID: 39615991
No abstract available.
8.
Auth J, Muller F, Volkl S, Bayerl N, Distler J, Tur C, et al.
Lancet Rheumatol
. 2024 Nov;
7(2):e83-e93.
PMID: 39542003
Background: CD19-targeting chimeric antigen receptor (CAR) T-cell therapy has shown remarkable outcomes in patients with systemic lupus erythematosus. The effects of CD19-targeting CAR T cells on organ manifestations in patients...
9.
Bteich Y, Assaf J, Muller F, Gendy J, Jacob S, Hafezi F, et al.
Cornea
. 2024 Nov;
44(3):360-367.
PMID: 39499155
Purpose: To evaluate the outcomes of patients treated with corneal allogeneic intrastromal ring segments cut with femtosecond laser (Femto-CAIRS) without concomitant corneal crosslinking. Methods: Patients with keratoconus treated with Femto-CAIRS...
10.
Djouoma N, Muller F, Stolle F, Hoffmann F, Thieme H, Hoffmann M, et al.
Sci Rep
. 2024 Oct;
14(1):25400.
PMID: 39455627
The Rapid Campimetry (RC), a kinetic visual field test proved to reliably detect visual field defects within the central 10° degrees, the most crucial part for visual acuity and quality...